Brazil's Anvisa bans unregistered tirzepatide/retatrutide pens

Brazil's health regulator Anvisa ordered seizure and banned sale, use, and advertising of peptide pens marketed as research products. This targets unregistered versions of GLP-1 drugs, likely to curb grey-market use. The move tightens regulatory enforcement but does not affect registered products.